Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) currently has a daily average trading volume of 1.16M but it saw 1007404 shares traded in last market. With a market cap of 63.90B USD, the company’s current market price of $591.85 came falling about -1.89 while comparing to the previous closing price of $603.26. In past 52 weeks, the stock remained buoying in the range of price level as high as $1211.20 and as low as $520.50. In the recent trading on the day, stock has struck highest price mark of $590.25 while lowest mark touched by it was $605.97.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Citigroup which upgraded the stock as “Buy” in its note to investors issued on May 14, 2025, recommending a price target of $700 for it. Leerink Partners also issued its recommendations for the stock as it upgraded the price target for the stock in the range of between $762 and $834.
Over the week, REGN’s stock price is moving -3.73% down while it is -3.11% when we observe its performance for the past one month. Year-to-date it is -16.91% down and over the past year, the stock is showing a downside performance of -39.64%.
The company is expected to be releasing its next quarterly report on 2025-Apr-28, for which analysts forecasted an EPS of 8.53 while estimate for next year EPS is 35.5. In next quarter, company is expected to be making quarterly sales of $3.44B as analysts are expecting the sales for current fiscal year at $13.47B and seeing the company making $14.32B in sales next year. Moreover, analysts are in estimates of $3.3B for current-quarter revenue.
Currently, Regeneron Pharmaceuticals, Inc’s total number of outstanding shares is 106.40M with 1.90% of that held by the insiders while 92.08% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 14.02% and return on equity (ROE) at 15.96%. It has a price to earnings ratio (P/E ratio) of 15.07 while having a 14.97 of forward P/E ratio. Stock’s beta reads 0.38. Stock has a price to book (P/B) ratio of 2.18 while price to sale or P/S ratio amounts to 4.54. Its return on asset (ROA) is 12.51% on average.
